Bod Science has submitted ethics approval for its delayed pharmacokinetics (PK) study to test the bioavailability of CBD using its Aqua Phase technology.
Recruitment for the four-week study will begin immediately, with 12 participants required. Ethics approval is expected in two weeks with results likely to be known in June.
Bod has previously indicated that Aqua Phase is expected to deliver bioavailability of more than 30% through a methodology which creates a molecule which is “truly soluble”, according to chief executive Jo Patterson.
Typically, CBD suspended in MCT oil delivers bioavailability of between 6% and 8%.
A successful PK study will trigger a GB£1 million (A$1.8m) payment to the inventors of Aqua Phase which Bod agreed to acquire last year.
Bod said it will also pave the way for commercial discussions, expand the company’s value proposition, create novel delivery formats, and deliver higher margins and revenue.
